Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Ms. Wai Har Ng at National Cancer Centre Singapore, Singapore.

Ms. Wai Har Ng is a Senior Research Associate at the National Cancer Centre Singapore with over two decades of experience in cancer biology and translational research. His scientific journey spans genetic engineering, molecular oncology, and personalized therapeutics, with a strong focus on hepatocellular carcinoma, peritoneal carcinomatosis, and colorectal cancer. A dynamic contributor to national research consortiums, Ng WH has authored numerous high-impact publications and excels in molecular, cellular, and in vivo experimental platforms. Known for his collaborative spirit, he plays a pivotal role in mentoring, protocol development, and driving clinical translation in cancer therapy through precision medicine and molecular marker discovery.

Publication Profile 

Scopus

Education

Ms. Wai Har Ng obtained a Master of Science in Genetic Engineering from Universiti Putra Malaysia (2005), where his dissertation focused on gene expression profiling of oil palm root systems using EST and microarray technology. He earned his Bachelor of Science in Biotechnology (2000) from the same university, working on Arabidopsis root transformation. His foundational education was completed at Chong Hwa Independent High School, Kuala Lumpur, from 1990–2000, with certifications including STPM, SPM, and SRP. His early academic training at SRJK (C) Tsun Jin laid the groundwork for a career defined by scientific curiosity, discipline, and innovation in molecular biosciences.

Experience 

Ms. Wai Har Ng currently serves as a Senior Research Associate at the National Cancer Centre Singapore (2017–present), where he spearheads research on molecular therapeutics and biomarker discovery. He previously worked as a Research Officer and Research Associate at the same institute (2004–2017), contributing to groundbreaking oncology studies. Earlier, he served at the Malaysian Agricultural Research & Development Institute (MARDI) from 2003–2004. His academic skillset spans molecular biology, proteomics, imaging, animal studies, and lab management. Proficient in BSL2 safety, grant collaboration, and multidisciplinary research, he plays a key role in mentoring, lab operations, and translational biomedical research.

Awards 

While specific awards were not listed, Ng WH’s achievements are evident through his prolific publication record in high-impact journals, participation in national research consortia like the Singapore Peritoneal Oncology Study (SPOS) and Singapore Gastric Cancer Consortium (SGCC), and recognition as a core contributor to precision oncology research. His co-authorship on influential studies in Scientific Reports, Cell Reports Medicine, and International Journal of Molecular Sciences demonstrates academic recognition and leadership. His technical versatility and mentorship roles further highlight his contribution to national cancer research excellence. If formal awards were earned, these would further bolster his already commendable profile.

Research Focus 

Ng WH focuses on translational cancer research with emphasis on hepatocellular carcinoma, colorectal cancer, peritoneal carcinomatosis, and liposarcoma. His work integrates drug synergy, molecular profiling, biomarker discovery, and machine learning to optimize personalized cancer therapies. He is proficient in CRISPR, ddPCR, organoid modeling, xenografts, and immunofluorescence microscopy. A key area includes developing predictive molecular signatures for chemotherapy response and leveraging advanced imaging to study tumor behavior. With over 13 peer-reviewed publications, Ng WH bridges basic science and clinical application, contributing to a future where cancer treatment is personalized, precise, and highly effective.

Publication Top Notes

  • Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach
  • Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma

Teodora-Eliana Petcov | Drug Delivery Systems | Best Researcher Award

Published on by Top Pharmaceutical

Teodora-Eliana Petcov | Drug Delivery Systems | Best Researcher Award

Ms. Teodora-Eliana Petcov at National University of Science and Technology POLITEHNICA Bucharest, Romania.

Teodora Eliana Petcov is a driven biomedical researcher with a strong foundation in biomaterials, molecular biology, and nanotechnology. Passionate about innovation in drug delivery and regenerative medicine, she has already co-authored scientific publications in reputed journals. Her international internships, multidisciplinary skills, and involvement in EU-funded research projects underscore her commitment to advancing medical technologies. Teodora balances research excellence with volunteer leadership, contributing to both academic and community-driven initiatives. With a sharp analytical mind, hands-on lab experience, and cross-cultural exposure, she exemplifies the next generation of biomedical scientists focused on improving patient care through science and innovation.

Publication Profile 

Scopus

Education

Teodora holds a Bachelor’s degree in Medical Engineering from the Polytechnic University of Bucharest  with a focus on biomaterials and medical devices. She is currently pursuing her Master’s in Biocompatible Substances, Materials, and Systems at the National University of Science and Technology POLITEHNICA Bucharest. Her thesis explored the internalization of nano-sized devices in biological structures. She was a visiting student at “Horia Hulubei” Nuclear Institute and Floreasca Emergency Hospital. Her academic path is complemented by certifications in English  and psycho-pedagogical training, showcasing both technical expertise and educational versatility.

Experience 

Teodora has completed multiple research internships, including roles in molecular biology and materials science labs. She gained practical expertise in 3D bioprinting, SEM techniques, SolidWorks, and conducted advanced testing like DSC and DMA. She has contributed to projects at the National Institute of Physics and Nuclear Engineering, University of Campania in Italy, and worked on PNRR-funded research on bone regeneration and multiple myeloma. Additionally, she has volunteered extensively in cultural and scientific event organization, holding assistant coordinator roles in Zenezia and MED, where she honed human resources, leadership, and scientific communication skills.

Awards  

Teodora has been recognized for her academic excellence and community involvement from high school through higher education. She received top honors for her Bachelor’s thesis, was selected for the prestigious ROSE program, and presented at the “Info-Practic” National Symposium on artificial intelligence. She participated in EU-supported initiatives like ERASMUS+ “Be a Buddy, Not a Bully” and contributed to major national projects, including the ongoing PNRR-funded research on personalized bone regeneration. Her work on cutting-edge nanostructures and her leadership in volunteer networks demonstrate her well-rounded excellence and dedication to scientific and societal progress.

Research Focus 

Teodora focuses on biomedical applications of nanotechnology, with a keen interest in targeted drug delivery, biopolymeric material synthesis, and regenerative medicine. Her Master’s research and publications revolve around understanding how nanostructures interact with cellular systems to improve treatment precision in diseases like multiple myeloma. She also explores the use of 3D printed biomaterials and advanced materials characterization techniques (SEM, DSC, DMA). Her interdisciplinary research combines materials science, molecular biology, and bioengineering to design patient-specific, low-toxicity solutions, positioning her at the frontier of precision and personalized medicine.

Publication Top Notes

Nanostructures: An efficient drug delivery platform for therapy of multiple myeloma — 2025 — Cited by 0

Journal: European Journal of Medicinal Chemistry Reports

Publication Date: June 13, 2025 

Conclusion

Teodora Eliana Petcov is a highly promising emerging researcher whose interdisciplinary approach, early scientific contributions, and strong practical expertise align closely with the vision of the Best Researcher Award. Her dedication to innovation in biomaterials, nanotechnology, and regenerative medicine showcases both depth and futuristic relevance.

Miao Zhou | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Miao Zhou | Precision Medicine | Best Researcher Award

Prof. Miao Zhou at Guangdong Provincial People’s Hospital, China.

Dr. Miao Zhou is a distinguished oral and maxillofacial specialist, currently serving as Chief Physician and Associate Director at the Stomatology Department of Guangdong Provincial People’s Hospital. He is also a supervisor of postgraduate and postdoctoral researchers. An innovator in oral regenerative medicine, he founded the 3D Bioprinting and Regenerative Medicine Branch of the Guangdong Society of Biomedical Engineering. His pioneering research bridges clinical practice and cutting-edge biotechnology, advancing solutions for complex craniofacial conditions. With deep expertise in biomaterials, stem cells, and exosomes, Dr. Zhou continues to drive impactful research and medical education in the fields of maxillofacial rehabilitation and tissue engineering.

Publication Profile 

Scopus

Education

Dr. Miao Zhou earned his Ph.D. in 2009 from Peking University, one of China’s top-tier institutions, where he focused on maxillofacial rehabilitation using functional biomaterials and tissue engineering. His doctoral thesis explored clinical solutions for oral and maxillofacial defects through bio-integrative materials and scaffold systems. This strong academic foundation laid the groundwork for his later interdisciplinary innovations in regenerative medicine. In addition to his formal education, Dr. Zhou has participated in numerous continuing education programs and scientific collaborations, refining his expertise in 3D printing, stem cell therapy, and implantology, and training the next generation of specialists in advanced dental medicine.

Experience

With over 15 years of clinical and research experience, Dr. Miao Zhou is a Chief Physician and Associate Director at Guangdong Provincial People’s Hospital’s Stomatology Department. He supervises both postgraduates and postdocs, guiding translational research in tissue regeneration. He has served as Principal Investigator on numerous national and provincial-level projects, especially in the application of 3D-printed biomimetic scaffolds and exosomes. As a research leader, Dr. Zhou has pioneered innovations in craniomaxillofacial bone regeneration and soft tissue reconstruction. His clinical expertise, combined with academic leadership, positions him as a key influencer in oral regenerative therapy and personalized medical biomaterial development.

Awards 

Dr. Zhou has received numerous accolades, including the First Prize for Excellent Paper at the 6th China International & 9th China Academic Conference of Oral and Maxillofacial Surgery. His recognition reflects significant contributions to clinical and translational research. He has been honored by national bodies such as the National Natural Science Foundation of China and the Guangzhou Healthcare Innovation Program for his leadership in 3D bioprinting and regenerative medicine. As the founder of the 3D Bioprinting and Regenerative Medicine Branch under the Guangdong Society of Biomedical Engineering, his efforts have helped shape emerging medical frontiers and drive collaborative innovation.

Research Focus 

Dr. Zhou’s research centers on 3D-printed biomimetic scaffolds, stem cell therapy, and exosome-based interventions for oral and maxillofacial regeneration. His work explores how engineered tissues and cell-based therapies can reconstruct large jaw defects, restore bone function, and integrate with host tissues. His studies focus on osteoinduction, vascularization, and personalized medicine approaches using biocompatible materials. By leveraging cutting-edge printing technologies and biomolecular signaling pathways, Dr. Zhou aims to bridge gaps between laboratory research and clinical application—delivering impactful solutions for tissue repair and oral implantology. His interdisciplinary approach integrates biomaterials science, dentistry, and regenerative medicine to redefine patient care.

Publication Top Notes

  • An engineered M2 macrophage-derived exosomes-loaded electrospun biomimetic periosteum promotes cell recruitment, immunoregulation, and angiogenesis in bone regeneration
  • Osteogenically committed hUCMSCs-derived exosomes promote the recovery of critical-sized bone defects with enhanced osteogenic properties
  • 3WJ RNA Nanoparticles-Aptamer Functionalized Exosomes From M2 MacrophagesTarget BMSCs to Promote the Healing of Bone Fractures

E Marimuthu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. E. Marimuthu | Drug Discovery and Development | Best Researcher Award

Professor at Arunachal University of Studies, Ayya Nadar Janaki Ammal College, Madurai Kamaraj University, India.

Dr. E. Marimuthu is a dedicated researcher and academician specializing in plant biotechnology, microbiology, and molecular biology. With over 15 years of experience in research and education, he has made significant contributions through patents, microbial sequencing, and ethnobotanical surveys. His work focuses on endangered species conservation, natural IAA production, and nanomedicine applications for cancer. Dr. Marimuthu currently serves as a Professor at Arunachal University of Studies. His multidisciplinary efforts bridge traditional knowledge with modern scientific innovations, making him a standout figure in applied life sciences and pharmaceutical biotechnology.

Publication Profile 

Scopus

Education

Dr. Marimuthu earned his Ph.D. from Madurai Kamaraj University in 2017, focusing on the in vitro conservation of endangered tree species in the Southern Western Ghats 🌳. He completed his M.Phil. and M.Sc. from Ayya Nadar Janaki Ammal College, conducting ethnomedicinal surveys and plant growth hormone studies 🌿. His academic foundation began with a B.Sc. in Botany. Each academic milestone has been rooted in biodiversity conservation and plant-microbe interactions, establishing a strong base for his later patents and microbial gene discoveries 🧪.

Experience

Dr. Marimuthu has held various academic and research roles: Professor and Associate Professor at Arunachal University of Studies (2023–present), Assistant Professor at Sri Vidya Mandir and Vivekanandha Colleges, and Associate Scientist at Aakash Green Research Pvt. Ltd 🏫. Earlier, he served as a JRF at TBGRI, Kerala 🌱 and Technical Assistant at Kalasalingam University. His experience spans plant tissue culture, cell line work, and microbial molecular studies. With deep involvement in both lab and field research, he has nurtured innovations from concept to patent, while also mentoring students and contributing to curriculum development.

Awards 

Dr. E. Marimuthu is a prolific innovator with 8 Indian patents and 2 Canadian patents, showcasing breakthroughs in nanomedicine, cancer immunotherapy, and plant-based biotechnology 🧬. His bacterial gene sequences are submitted to NCBI, emphasizing novel microbial discoveries from unique ecological niches 🧫. Recognized nationally and internationally for his translational research, he has pioneered techniques that merge traditional plant knowledge with high-end scientific platforms. Though specific named awards are not listed, his patent record and academic promotions signify a distinguished and respected trajectory in bioscience innovation and interdisciplinary research.

Research Focus 

Dr. Marimuthu’s research emphasizes plant tissue culture, natural growth hormone production, ethnomedicinal conservation, and nanotechnology-enhanced drug delivery 💊. He explores molecular markers for documenting genetic diversity and has successfully isolated bacterial strains producing Indole-3-acetic acid (IAA) to promote plant growth 🌾. He integrates ethnobotanical knowledge with biotechnological advancements to develop eco-friendly, scalable solutions for agriculture and medicine. His cutting-edge work in cancer-targeting mesenchymal stem cell therapy, as well as nano-immunotherapy, reflects a visionary outlook on the future of personalized medicine and sustainable pharmacology.

Publication Top Notes

A study on the ethnomedical knowledge of the Malappandaram Tribe in Pathanamthitta and Kollam districts of Kerala, India

Journal: Journal of Molecular Structure (Elsevier) 
Publication Date: July 14, 2025

Conclusion

Dr. E. Marimuthu is an outstanding candidate for the Best Researcher Award, showcasing a rare combination of field knowledge, lab precision, patent-oriented innovation, and a commitment to both fundamental and applied science. His work contributes significantly to biotechnology, pharmacology, environmental microbiology, and regenerative agriculture.

Meixian Zhang | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Meixian Zhang | Clinical Trials | Best Researcher Award

Director at Taizhou Hospital of Zhejiang Province, China.

Dr. Meixian Zhang is an Associate Researcher and Master’s Supervisor at Wenzhou Medical University. With a Ph.D. in Public Health, she specializes in clinical epidemiology, evidence-based medicine, and obesity research. Her career is marked by over 35 SCI journal publications and leadership in multiple national and provincial research projects. She is deeply committed to tackling childhood obesity through genetic and dietary studies. With a passion for translational health research and mentoring, Dr. Zhang has earned recognition through innovation, impactful findings, and dedicated academic service. She continues to push boundaries in the fight against obesity-related health risks.

Publication Profile 

Orcid

Education

Dr. Zhang Meixian earned her Ph.D. in Public Health, specializing in childhood obesity and molecular epidemiology. Her academic journey began with a strong foundation in clinical medicine and public health, followed by doctoral research focusing on genetic predisposition to pediatric adiposity. She has been trained extensively in clinical epidemiology, biostatistics, and molecular genetics. Her postgraduate training enabled her to explore multifaceted aspects of obesity-related metabolic disorders and the implementation of evidence-based interventions. The academic rigor and scientific integrity developed during her education continue to guide her ongoing contributions to translational research and public health education.

Experience

With over a decade of research and academic experience, Dr. Zhang currently serves as an Associate Researcher at Wenzhou Medical University. She has supervised graduate students and led numerous scientific projects as principal investigator. Her work bridges molecular epidemiology, public health policy, and clinical research. She’s received major grants from the National Natural Science Youth Fund and Zhejiang provincial programs. She has also contributed to high-impact studies on obesity, SNPs, and weight management. Through editorial appointments and cross-institution collaborations, she continues to expand the reach of her research across China and the global scientific community.

Awards 

Dr. Zhang has received significant recognition for her contributions to medical research. She has been awarded grants from the National Natural Science Youth Fund and the Basic Public Welfare Research Program of Zhejiang Province as a Principal Investigator. Additionally, she has secured two provincial-level medical and science grants and one from the Taizhou Science and Technology Council. Her innovative research has led to two authorized national invention patents and one software copyright. These accolades underscore her scientific excellence and translational impact in obesity and metabolic health, positioning her as a leading figure in evidence-based public health research.

Research Focus 

Dr. Zhang’s research centers on childhood obesity, metabolic syndrome, and genetic susceptibility markers. She investigates the role of leptin, adiponectin, FTO gene variants, and other biomarkers in the development of obesity. Her work bridges molecular epidemiology with clinical nutrition, validating interventions such as intermittent fasting, calorie restriction, and meal replacements. Additionally, she explores single-nucleotide polymorphisms (SNPs) and their regulatory functions in metabolic pathways. Dr. Zhang’s interdisciplinary approach integrates public health, genomics, and preventive medicine, aiming to deliver targeted health strategies for pediatric populations in China and globally.

Top Publications

Willingness of Older Adults with Chronic Diseases to Receive a Booster Dose of Inactivated Coronavirus Disease 2019 Vaccine: A Cross-Sectional Study in Taizhou, China — 2022 — Cited by 0

Conclusion

Dr. Zhang Meixian’s academic rigor, originality, and focused contributions in combating obesity through evidence-based and genetics-informed approaches position her as an outstanding candidate for the Best Researcher Award. Her ability to translate complex research into meaningful public health solutions, combined with her strong record of funding, publications, and innovation, make her a worthy and impactful recipient of this recognition. With minor strategic advancements, her global influence is poised to grow even further.

Rulla Tamimi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Rulla Tamimi | Immunotherapy | Best Researcher Award

Dr. Rulla Tamimi at Weill Cornell Medicine Dept of Healthcar, United States.

Dr. Rulla M. Tamimi is a leading cancer epidemiologist and Professor of Population Health Sciences and Pathology at Weill Cornell Medicine. With over two decades of experience in breast cancer research, her work centers on cancer risk prediction, environmental exposures, and molecular epidemiology. A pioneer in integrating biomarkers and epidemiologic data, she has advanced understanding of breast cancer heterogeneity and disparities. Dr. Tamimi is also a principal investigator for multiple NIH-funded studies and a dedicated educator. She plays a critical role in shaping future public health strategies and improving women’s health through rigorous research and community-engaged science.

Publication Profile 

Scopus

Education

Dr. Tamimi holds a B.S. in Biology from Tufts University (1993), followed by an M.S. (1999) and Sc.D. (2003) in Epidemiology from the Harvard T.H. Chan School of Public Health. Her academic training is rooted in public health, statistical methods, and cancer epidemiology. She received advanced training at Harvard, which set the stage for a prolific research and academic career in molecular and clinical epidemiology. Her education enabled her to translate complex biological mechanisms into population-level cancer prevention strategies, and her leadership has consistently bridged rigorous epidemiological research with patient-focused public health innovation.

Experience

Dr. Tamimi has held prestigious academic positions including Instructor, Assistant Professor, Associate Professor at Harvard Medical School and Harvard T.H. Chan School of Public Health (2003–2020). She currently serves as Professor at Weill Cornell Medicine (2020–Present). With over 20 years in academic medicine, she’s also served as Associate Epidemiologist at Brigham and Women’s Hospital. Dr. Tamimi leads NIH- and NCI-funded multi-institutional projects, mentoring future epidemiologists while advancing cancer research. She has contributed to global education through lectures and program direction across institutions including Boston University, Harvard, and National University of Singapore.

Awards 

Dr. Tamimi has received multiple accolades for her visionary research. She earned the “Good Questions Meet Big Data” Ideation Challenge Award from Harvard Catalyst in 2017 and became a Susan G. Komen Scholar in 2020. Her election to prominent organizations such as the American Association for Cancer Research, Society for Epidemiologic Research, and Cornell Center for Health Equity highlights her influence in the field. These recognitions reflect her leadership in molecular epidemiology, commitment to health equity, and significant contributions to cancer prevention research on both national and global scales.

Research Focus 

Dr. Tamimi’s research explores breast cancer heterogeneity, environmental exposures, and the biological underpinnings of cancer risk. Her projects evaluate how dietary carotenoids, genetic variants, circulating metabolites, and breast tissue markers influence cancer outcomes. She is especially interested in aggressive tumor subtypes, breast cancer in young women, and disparities across racial and socioeconomic lines. Current studies also examine stromal contributions to carcinogenesis and social determinants of health through the SoCa Center. Her work connects molecular biology with epidemiological insights to improve early detection, prevention, and personalized treatment strategies for breast cancer.

Publication Top Notes

  • Regular aspirin use, breast tumor characteristics and long-term breast cancer survival
  • Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts
  • Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States
  • Thromboembolic Events Are Increased After Splenectomy in Postmenopausal Women
  • The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages
  • The impact of reproductive factors on breast tumor and normal-adjacent tissue immune profile from menarche to menopause
  • Associations of alcohol consumption with expression of CD44, CD24, and ALDH1A1 stem cell markers in benign breast biopsy samples
  • Breast cancer prevention by short-term inhibition of TGFβ signaling
  • Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study
  • A genome-wide association study of mammographic texture variation

Alexis LeVee | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Alexis LeVee | Oncology Pharmaceuticals | Best Researcher Award

Dr. Alexis LeVee at UCLA, United States.

Dr. A. LeVee is a physician-scientist specializing in medical oncology with a focus on breast cancer and translational immunotherapy. Currently a Clinical Instructor at UCLA and a Hematology/Oncology Fellow at City of Hope, Dr. LeVee combines clinical expertise with cutting-edge research in tumor immunology, the microbiome, and novel therapeutic biomarkers. A graduate of Duke University and Tufts Medical School, they are a recipient of multiple national awards, including the ASCO Conquer Cancer Young Investigator Award. With over 10 peer-reviewed publications and leadership in high-impact studies, Dr. LeVee is shaping the future of personalized cancer care and precision immunotherapy.

Publication Profile 

Google Scholar

Education

Dr. LeVee earned a B.A. in Chemistry with minors in Economics and Biology from Duke University (2013) 🧪, followed by an M.D. from Tufts University School of Medicine (2019) 🩺. They completed an Internal Medicine residency at Cedars-Sinai Medical Center (2019–2022) and are currently completing a Hematology/Medical Oncology Fellowship at City of Hope Comprehensive Cancer Center (2022–2025) 🧠. Their diverse training spans top-tier academic institutions and reflects a deep foundation in both clinical medicine and biomedical sciences, equipping them with the tools to integrate research and practice in complex oncology care.

Experience

Dr. LeVee currently serves as Clinical Instructor at UCLA (2025–Present) and Chief Fellow at City of Hope (2023–Present) in the Hematology/Medical Oncology Fellowship Program. Previously, they worked as a Business Analyst at Orange Advisory Group (2013–2015), combining data-driven insight with clinical research. Dr. LeVee has held numerous leadership and committee roles at Cedars-Sinai and City of Hope, contributing to medical education and institutional quality improvement. Their multidisciplinary background and academic leadership experience reflect a strong trajectory toward becoming a leader in translational oncology and academic medicine.

Awards 

Dr. LeVee has earned multiple prestigious awards, including the Young Investigator Award from ASCO, Conquer Cancer Foundation, and MOASC 🏆. Additional accolades include the Coltman Scholar Award and Early Investigator Award from the San Antonio Breast Cancer Symposium (2024), the ASCO Merit Award (2024), and finalist status for the Rubenstein Award for Resident Research (2022). Earlier honors include fellowships from Tufts, American Thoracic Society, and DukeEngage. These awards reflect their innovative research and impact in oncology, particularly in microbiome science, breast cancer immunotherapy, and biomarker discovery.

Research Focus 

Dr. LeVee’s research bridges clinical oncology and translational science, focusing on breast cancer, tumor microenvironment, and immunotherapy 🧬. Their work investigates how microbiota, immune signatures, and biomarkers predict treatment response in triple-negative and HER2+ breast cancers. With funding from ASCO, Biocodex, and City of Hope, Dr. LeVee leads multiple studies analyzing metagenomic and metatranscriptomic profiles of fecal microbiota in patients receiving chemoimmunotherapy. They also explore the cardiotoxic effects of cancer therapies and immuno-radiation synergy. Their goal is to develop precision tools that enhance treatment personalization and patient outcomes in cancer care.

Publication Top Notes

Efthalia Moustakli | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Efthalia Moustakli | Pharmacology | Best Researcher Award

Dr. Efthalia Moustakli at University of Ioannina, School of Health Sciences, Greece.

Dr. Efthalia Moustakli, a PhD-trained biologist, excels in medical genetics, molecular biology, and bioinformatics. Currently a postdoctoral researcher and adjunct professor, she integrates clinical, wet-lab, and computational techniques to drive real-world healthcare innovation. With extensive experience in translational science and academic mentorship, she bridges the gap between research and clinical application. Her dedication to advancing reproductive medicine and aging research is reflected in 30+ high-impact publications. Recognized for academic excellence and research leadership, she exemplifies commitment to impactful science and interdisciplinary collaboration across education, technology, and medicine.

Publication Profile 

Google Scholar

Education

Dr. Efthalia Moustakli earned her PhD in Medical Genetics from the University of Ioannina, Greece, with her dissertation graded “Excellent” and focused on telomere and mitochondrial recombination in spermatozoa. She previously completed an Integrated Master’s in Biological Applications and Technology, also from the University of Ioannina, where her thesis on genetic abnormalities. Her academic journey reflects a strong foundation in genetics, genomics, and reproductive biology, complemented by international training in Germany, showcasing her commitment to advancing precision and reproductive medicine through rigorous scientific research and interdisciplinary learning.

Experience

Dr. Efthalia Moustakli is currently a Postdoctoral Researcher at the Department of Informatics and Telecommunications, University of Ioannina, focusing on molecular aging and bioinformatics. She also serves as an Adjunct Professor in the Nursing Department. Previously, she worked as a Junior Embryologist at Genesis Athens, a Molecular Biologist on the EU-funded PathAge project, and as a trainee in Germany at Universitätsklinikum Jena. Her experience spans clinical research, wet-lab diagnostics, data analysis, and teaching, highlighting her ability to navigate both academia and real-world clinical settings with excellence and innovation.

Awards 

Dr. Efthalia Moustakli has been recognized for her exceptional contributions to reproductive science and molecular biology, earning top academic grades in both her PhD and Integrated Master’s programs. Her work on oxidative stress, microRNAs, and genetic diagnostics has gained international attention through 30+ peer-reviewed publications. She has actively contributed to EU-funded research projects and presented findings at major conferences. Her unique blend of clinical embryology, teaching, and algorithm development distinguishes her as a well-rounded scientist. A strong candidate for the Best Researcher Award, she exemplifies academic rigor, innovation, and interdisciplinary impact.

Research Focus 

Dr. Efthalia Moustakli specializes in reproductive health, infertility, oxidative stress, NGS data meta-analysis, and clinical genetics. Her postdoctoral work delves into the molecular mechanisms of aging, particularly in relation to telomeres and mitochondrial function. Through projects like PathAge, she integrates computational approaches with clinical data to enhance diagnostic and therapeutic insights. Her research interests span microbiome impacts, ART (Assisted Reproductive Technology), and biomarkers for reproductive outcomes, aiming to translate molecular findings into practical healthcare improvements. She combines bioinformatics, wet-lab, and clinical insight to support advances in personalized and preventative medicine.

Publication Top Notes

Hejian Zou | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Hejian Zou | Clinical Trials | Best Researcher Award

Dr. Hejian Zou at Huashan Hospital, Fudan University, China.

Dr. Hejian Zou is a renowned physician-scientist in the fields of rheumatology and immunology, with over three decades of academic and clinical experience. He earned his medical degree from Shanghai Medical University and steadily rose through the academic ranks, becoming a professor in 2003. A prolific researcher and clinician, he has led numerous national research projects focusing on autoimmune mechanisms, macrophage polarization, and innovative therapies for gout and arthritis. He has published extensively in high-impact journals and holds multiple patents. Dr. Zou has also authored influential books and serves on editorial boards of several prominent medical journals. He plays a critical leadership role at Huashan Hospital, Fudan University, and in several major national and international professional associations. Through his pioneering research, teaching, and clinical innovations, Dr. Zou has significantly advanced the understanding and treatment of autoimmune and connective tissue diseases in China and beyond.

Publication Profile 

Orcid

Education

Professor Hejian Zou began his academic journey at Shanghai Medical University, graduating in 1987 with a six-year degree in medical sciences. He continued at the same institution, earning a Doctor of Medicine degree in 1992 from the university’s prestigious graduate school. His educational path laid a strong foundation in both theoretical and clinical medicine, especially in immunology and rheumatology. Throughout his medical training, he demonstrated a profound interest in chronic inflammatory diseases, which later became his central research focus. His academic accomplishments led to successive promotions: he became an associate professor in 1994, a chief physician in 1999, and achieved the rank of full professor in 2003. His academic pedigree and continuous involvement in both teaching and research reflect a lifelong dedication to medical education, innovation, and mentoring the next generation of physicians and researchers in the field of autoimmune disorders and connective tissue diseases.

Experience

Professor Zou has built a distinguished career marked by excellence in clinical medicine, academic leadership, and scientific research. He currently serves as a professor and head of rheumatology and immunology at Huashan Hospital, Fudan University, one of China’s premier medical institutions. Over the years, he has led several national research projects, including studies on macrophage polarization in gout, follicular helper T cells in SLE, and T regulatory cell therapy for arthritis. With a citation index exceeding 2600, his publications have influenced both Chinese and global rheumatology. He has actively contributed to medical education, mentoring students and young researchers. In parallel, Dr. Zou has worked on translational research, holding patents for novel gout therapies. His role extends to editorial and advisory positions in key medical journals and organizations. His comprehensive expertise and commitment have established him as a leading voice in rheumatology across clinical, academic, and scientific communities.

Awards 

Professor Hejian Zou’s pioneering work has earned him numerous accolades in the field of rheumatology and immunology. He has been a recipient of national research funding awards for his studies on autoimmune diseases, including three major projects under the National Natural Science Foundation of China. He has also received multiple patents for his discoveries in gout therapies, showcasing his commitment to translational and impactful research. Professor Zou is a Vice Chairman of The International Network of Scleroderma Clinical Care and Research (InSCAR) and holds top roles in major Chinese medical associations. His inclusion in editorial boards of renowned journals like the Journal of Chinese Rheumatology and Practical Internal Medicine further reflects his scientific stature. Recognized for both clinical excellence and research, Dr. Zou is a frequent speaker at international conferences, representing China on the global rheumatology stage. His achievements continue to inspire emerging researchers and clinicians worldwide.

Research Focus 

Professor Hejian Zou’s research focuses on autoimmune and connective tissue diseases, with a strong emphasis on gout, systemic lupus erythematosus (SLE), and rheumatoid arthritis. He explores the cellular and molecular mechanisms behind chronic inflammation and immune dysregulation, particularly macrophage polarization, regulatory T cell therapy, and follicular helper T cell function. His projects aim to develop targeted therapies that improve patient outcomes in autoimmune conditions. A pioneer in translational medicine, he has patented natural and pharmacological agents—such as paeoniflorin and melatonin—for the treatment of gout. His approach combines basic immunology, experimental therapeutics, and clinical trials, enabling bench-to-bedside innovation. He actively collaborates with national institutions, mentors young scientists, and publishes widely in SCI-indexed journals. His lab’s work not only contributes to the understanding of autoimmune pathogenesis but also to drug development and personalized treatment strategies for chronic inflammatory diseases.

Publication Top Notes

  • Spatial multiomics decipher fibroblast–macrophage dynamics in systemic sclerosis

  • A Common Functional Variant at the Enhancer of the Rheumatoid Arthritis Risk Gene ORMDL3 Regulates its Expression Through Allele-Specific JunD Binding